stats FreshPatents Stats
n/a views for this patent on
Updated: August 12 2014
newTOP 200 Companies filing patents this week

    Free Services  

  • Enter keywords & we'll notify you when a new patent matches your request (weekly update).

  • Save & organize patents so you can view them later.

  • RSS rss
  • Create custom RSS feeds. Track keywords without receiving email.

  • View the last few months of your Keyword emails.

  • Patents sorted by company.

Follow us on Twitter
twitter icon@FreshPatents

Chemical compounds

last patentdownload pdfdownload imgimage previewnext patent

20120277258 patent thumbnailZoom

Chemical compounds

Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

Inventors: Amogh Boloor, Mui Cheung, Philip Anthony Harris, Kevin Hinkle, Christopher P. Laudeman, Jeffrey Alan Stafford, James Marvin Veal
USPTO Applicaton #: #20120277258 - Class: 514275 (USPTO) - 11/01/12 - Class 514 
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) >Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai >Hetero Ring Is Six-membered Consisting Of Two Nitrogens And Four Carbon Atoms (e.g., Pyridazines, Etc.) >1,4-diazine As One Of The Cyclos >Nitrogen Bonded Directly To The 1,3-diazine At 2-position By A Single Bond

view organizer monitor keywords

The Patent Description & Claims data below is from USPTO Patent Application 20120277258, Chemical compounds.

last patentpdficondownload pdfimage previewnext patent


The present invention relates to pyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such pyrimidine derivatives are useful in the treatment of diseases associated with inappropriate or pathological angiogenesis.

The process of angiogenesis is the development of new blood vessels from the pre-existing vasculature. Angiogenesis is defined herein as involving: (i) activation of endothelial cells; (ii) increased vascular permeability; (iii) subsequent dissolution of the basement membrane and extravasation of plasma components leading to formation of a provisional fibrin gel extracellular matrix; (iv) proliferation and mobilization of endothelial cells; (v) reorganization of mobilized endothelial cells to form functional capillaries; (vi) capillary loop formation; and (vi) deposition of basement membrane and recruitment of perivascular cells to newly formed vessels. Normal angiogenesis is active during tissue growth from embryonic development through maturity and then enters a period of relative quiescence during adulthood. Normal angiogenesis is also activated during wound healing, and at certain stages of the female reproductive cycle. Inappropriate or pathological angiogenesis has been associated with several disease states including various retinopathies, ischemic disease, atherosclerosis, chronic inflammatory disorders, and cancer. The role of angiogenesis in disease states is discussed, for instance, in Fan et al, Trends in Pharmacol Sci. 16:54-66; Shawver et al, DDT Vol. 2, No. 2 Feb. 1997; Folkmann, 1995, Nature Medicine 1:27-31.

In cancer the growth of solid tumors has been shown to be dependent on angiogenesis. The progression of leukemias as well as the accumulation of fluid associated with malignant ascites and pleural effusions also involve pro-angiogenic factors. (See Folkmann, J., J. Nat\'l. Cancer Inst., 1990, 82, 4-6.) Consequently, the targeting of pro-angiogenic pathways is a strategy being widely pursued in order to provide new therapeutics in these areas of great, unmet medical need.

Central to the process of angiogenesis are vascular endothelial growth factor (VEGF) and its receptors, termed vascular endothelial growth factor receptor(s) (VEGFRs), The roles VEGF and VEGFRs play in the vascularization of solid tumors, progression of hematopoietic cancers and modulation of vascular permeability have drawn great interest in the scientific community. VEGF is a polypeptide, which has been linked to inappropriate or pathological angiogenesis (Pinedo, H. M. et al The Oncologist, Vol. 5, No. 90001, 1-2, April 2000). VEGFR(s) are protein tyrosine kinases (PTKs) that catalyze the phosphorylation of specific tyrosine residues in proteins that are involved in the regulation of cell growth, differentiation, and survival. (A. F. Wilks, Progress in Growth Factor Research, 1990, 2, 97-111; S. A. Courtneidge, Dev. Supp. I, 1993, 57-64; J. A. Cooper, Semin. Cell Biol., 1994, 5(6), 377-387; R. F. Paulson, Semin. Immunol., 1995, 7(4), 267-277; A. C. Chan, Curr. Opin. Immunol., 1996, 8(3), 394-401).

Three PTK receptors for VEGF have been identified: VEGFR1 (Flt-1); VEGFR2 (Flk-1 and KDR) and VEGFR3 (Flt-4). These receptors are involved in angiogenesis and participate in signal transduction. (Mustonen, T. et al J. Cell Biol. 1995:129:895-898; Ferrara and Davis-Smyth, Endocrine Reviews, 18(1):4-25, 1997; McMahon, G., The Oncologist, Vol. 5, No 90001, 3-10, April 2000).

Of particular interest is VEGFR2, which is a transmembrane receptor PTK expressed primarily in endothelial cells. Activation of VEGFR-2 by VEGF is a critical step in the signal transduction pathway that initiates tumor angiogenesis. VEGF expression may be constitutive to tumor cells and can also be upregulated in response to certain stimuli. One such stimulus is hypoxia, where VEGF expression is upregulated in both tumor and associated host tissues. The VEGF ligand activates VEGFR2 by binding to its extracellular VEGF binding site. This leads to receptor dimerization of VEGFRs and autophosphorylation of tyrosine residues at the intracellular kinase domain of VEGFR2. The kinase domain operates to transfer a phosphate from ATP to the tyrosine residues, thus providing binding sites for signaling proteins downstream of VEGFR-2 leading ultimately to angiogenesis. (Ferrara and Davis-Smyth, Endocrine Reviews, 18(1):4-25, 1997; McMahon, G., The Oncologist, Vol. 5, No. 90001, 3-10, April 2000.)

Consequently, antagonism of the VEGFR2 kinase domain would block phosphorylation of tyrosine residues and serve to disrupt initiation of angiogenesis. Specifically, inhibition at the ATP binding site of the VEGFR2 kinase domain would prevent binding of ATP and prevent phosphorylation of tyrosine residues. Such disruption of the pro-angiogenesis signal transduction pathway associated with VEGFR2 should therefore inhibit tumor angiogenesis and thereby provide a potent treatment for cancer or other disorders associated with inappropriate angiogenesis.

The present inventors have discovered novel pyrimidine derivative compounds, which are inhibitors of VEGFR-2 kinase activity. Such pyrimidine derivatives are useful in the treatment of disorders, including cancer, associated with inappropriate angiogenesis.




In one aspect of the present invention, there is provided a compound of Formula (I):

or a salt, solvate, or physiologically functional derivative thereof: wherein:

D is

X1 is hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 hydroxyalkyl; X2 is hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, C(O)R1, or aralkyl; X3 is hydrogen or halogen; X4 is hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, heteroaralkyl, cyanoalkyl, —(CH2)pC═CH(CH2)tH, —(CH2)pC≡C(CH2)tH, or C3-C7 cycloalkyl; p is 1, 2, or 3; t is 0 or 1; W is N or C—R, wherein R is hydrogen, halogen, or cyano; Q1 is hydrogen, halogen, C1-C2 haloalkyl, C1-C2 alkyl, C1-C2 alkoxy, or C1-C2 haloalkoxy;

Q2 is A1 or A2;

Q3 is A1 when Q2 is A2 and Q3 is A2 when Q2 is A1; wherein

A1 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, —OR1, and

A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1, 2, or 3, or Z is NR2 and m is 0 or 1, or Z is oxygen and m is 0 or 1, or Z is CH2NR2 and m is 0 or 1; Z1 is S(O)2, S(O), or C(O); and Z2 is C1-C4 alkyl, NR3R4, aryl, arylamino, aralkyl, aralkoxy, or heteroaryl, R1 is C1-C4 alkyl;

Download full PDF for full patent description/claims.

Advertise on - Rates & Info

You can also Monitor Keywords and Search for tracking patents relating to this Chemical compounds patent application.
monitor keywords

Keyword Monitor How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.  
Start now! - Receive info on patent apps like Chemical compounds or other areas of interest.

Previous Patent Application:
Frequency modulated drug delivery (fmdd)
Next Patent Application:
Substituted benzofused derivatives and their use as vanilloid receptor ligands
Industry Class:
Drug, bio-affecting and body treating compositions
Thank you for viewing the Chemical compounds patent info.
- - - Apple patents, Boeing patents, Google patents, IBM patents, Jabil patents, Coca Cola patents, Motorola patents

Results in 0.99016 seconds

Other interesting categories:
Computers:  Graphics I/O Processors Dyn. Storage Static Storage Printers


Data source: patent applications published in the public domain by the United States Patent and Trademark Office (USPTO). Information published here is for research/educational purposes only. FreshPatents is not affiliated with the USPTO, assignee companies, inventors, law firms or other assignees. Patent applications, documents and images may contain trademarks of the respective companies/authors. FreshPatents is not responsible for the accuracy, validity or otherwise contents of these public document patent application filings. When possible a complete PDF is provided, however, in some cases the presented document/images is an abstract or sampling of the full patent application for display purposes. Terms/Support

FreshNews promo

stats Patent Info
Application #
US 20120277258 A1
Publish Date
Document #
File Date
Other USPTO Classes
International Class

Follow us on Twitter
twitter icon@FreshPatents